The differences in the histological types of breast cancer and the response to neoadjuvant chemotherapy: The relationship between the outcome and the clinicopathological characteristics

Breast

Volumn 21, Issue 3, 2012, Pages 289-295

  Nagao, Tomoya ^a   Kinoshita, Takayuki ^a   Hojo, Takashi ^a   Tsuda, Hitoshi ^a   Tamura, Kenji ^a   Fujiwara, Yasuhiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Breast cancer; Histological type; Molecular subtypes; Neoadjuvant chemotherapy; Outcome

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; PACLITAXEL; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; APOCRINE CARCINOMA; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG RESPONSE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; MASTECTOMY; MUCINOUS CARCINOMA; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

EID: 84862528416     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2011.12.011     Document Type: Article

References (45)

1. The Japanese Breast Cancer Society General rules for clinical and pathological recording of breast cancer 2008, (in Japanese), Kanehara, Tokyo, 18-25. 16th ed.
2. The Japanese Breast Cancer Society Histological classification. Breast Cancer 2005, 12(Suppl.):S12-S14.
3. The World Health Organization The World Health Organization histological typing of breast tumors second edition. Am J Clin Pathol 1983, 78:806-816.
4. Buzdar A.U., Singletary S.E., Theriault R.L., Booser D.J., Valero V., Ibrahim N., et al. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operative breast cancer. J Clin Oncol 1999, 17:3412-3417.
5. Green M.C., Buzdar A.U., Smith T., Ibrahim N.K., Valero V., Rosales M.F., et al. Weekly paclitaxel improves pathologic complete remisson in operative breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 2005, 23:5983-5992.
6. Goldstein L., O'Neill A., Sparano J., Perez E., Shulman L., Martino S., et al. E2197: Phase III AT (doxorubicin/docetaxel) vs. AC (doxorubicin/cyclophosphamide) in the adjuvant treatment of node positive and high risk node negative breast cancer. J Clin Oncol 2005, 23(June 1 Suppl.):16S. 512.
7. Burstein H.J., Harris L.N., Gelman R., Lester S.C., Nunes R.A., Kaelin C.M., et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol 2003, 21:46-53.
8. Elston C.W., Ellis I.O. Pathological prognostic factors in breast cancer. I. The value of histopathological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991, 19:403-410.
9. Therasse P., Arbuck S.G., Eisenhauer E.A., Wandews J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000, 92:205-216.
10. Kurosumi M., Akashi-Tanaka S., Akiyama F., Komoike Y., Mukai H., Nakamura S., et al. Histopathological criteria for assessment of therapeutic response in breast cancer (2007 version). Breast Cancer 2008, 15:5-7.
11. Goldhirsch A., Glick J.H., Gelber R.D., Senn H.J. Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 1998, 90:1601-1608.
12. Goldhirsch A., Glick J.H., Gelber R.D., Coates A.S., Senn H.J. Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Clin Oncol 2001, 19:3817-3827.
13. Goldhirsch A., Wood W.C., Gelber R.D., Coates A.S., Thürlimann B., Senn H.J. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003, 21:3357-3365.
14. Goldhirsch A., Glick J.H., Gelber R.D., Coates A.S., Thürlimann B., Senn H.J. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005, 16:1569-1583.
15. Goldhirsch A., Wood W.C., Gelber R.D., Coates A.S., Thürlimann B., Senn H.J. Progress and promise: highlights of international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007, 18:1133-1144.
16. Wolmark N., Wang J., Mamounas E., Bryant J., Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001, 30:96-102.
17. Mauri D., Pavlidis N., Ioannidis J.P. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 2005, 97:188-194.
18. Saverio S.D., Gutierrez J., Avisar E. A retrospective review with long term follow up 11,400 cases of pure mucinous breast carcinoma. Breast Cancer Res Treat 2008, 111:541-547.
19. Yamaguchi J., Akashi-Tanaka S., Fukutomi T., Kinoshita T., Iwamoto E., Takasugi M. A case of mucinous carcinoma of the breast that demonstrated a good pathological response to neoadjuvant chemotherapy despite a poor clinical response. Breast Cancer 2006, 13:100-103.
20. Takeuchi H., Tsuji K., Ueo H., Kano T., Maehara Y. Clinicopathological feature and long-term prognosis of apocrine carcinoma of the breast in Japanese women. Breast Cancer Res Treat 2004, 88:49-54.
21. Tanaka K., Imoto S., Wada N., Sakemura N., Hasebe K. Invasive apocrine carcinoma of the breast: clinicopathologic features of 57 patients. Breast J 2008, 14:164-168.
22. Pezzi C.M., Patel-Parekh L., Cole K., Franko J., Klimberg V.S., Bland K. Characteristics and treatment of metaplastic breast cancer: analysis of 892 cases from the National Cancer Data Base. Ann Surg Oncol 2007, 14:166-173.
23. Luini A., Aguilar M., Gatti G., Fasani R., Botteri E., Brito J.A.D., et al. Metaplastic carcinoma of the breast, an unusual disease with worse prognosis: the experience of the European Institute of Oncology and review of the literature. Breast Cancer Res Treat 2007, 101:349-353.
24. Wargtoz E.S., Norris H.J. Metaplastic carcinomas of the breast. I. Matrix-producing carcinoma. Hum Path 1989, 20:628-635.
25. Wargtoz E.S., Does P.H., Norris H.J. Metaplastic carcinomas of the breast. II. Spindle cell carcinoma. Hum Path 1989, 20:732-740.
26. Wargtoz E.S., Norris H.J. Metaplastic carcinomas of the breast. III. Carcinosarcoma. Cancer 1989, 64:1490-1499.
27. Wargtoz E.S., Norris H.J. Metaplastic carcinomas of the breast. IV. Squamous cell carcinoma of ductal origin. Cancer 1990, 65:272-276.
28. Wargtoz E.S., Norris H.J. Metaplastic carcinomas of the breast. V. Metaplastic carcinoma with osteoclastic giant cells. Hum Path 1990, 21:1142-1150.
29. Rayson D., Adjei A.A., Suman V.J., Wold L.E., Ingle J.N. Metaplastic breast cancer: prognosis and response to systemic therapy. Ann Oncol 1999, 10:413-419.
30. Brown-Glaberman U., Graham A., Stopeck A. A case of metaplastic carcinoma of the breast responsive to chemotherapy with ifofamide and etoposide: improved antitumor respmnse by targeting sarcomatous features. Breast J 2010, 16:663-665.
31. Cocquyt V.F., Blondeel P.N., Depypere H.T., Preat M.M., Schelfhout V.R., Silva O.E., et al. Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma. Eur J Surg Oncol 2003, 29:361-367.
32. Wasif N., Maggard M.A., Ko C.Y., Giulianao A.E. Invasive lobular vs. ductal breast cancer; a stage-matched comparison of outcomes. Ann Surg Oncol 2010, 17:1862-1869.
33. Cristofanilli M., Gonzalez-Angulo A., Sneige N., Kau S.W., Broglio K., Theriault R.L., et al. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol 2005, 23:41-48.
34. Tubiana-Hulin M., Stevers D., Lasry S., Guinebretire J.M., Bouita L., Cohen-Solal C., et al. Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution. Ann Oncol 2006, 17:1228-1233.
35. Sørlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874.
36. Sørlie T., Tibshirani R., Parker J., Hastie T., Marron J.S., Nobel A., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003, 100:8418-8423.
37. Guarneri V., Broglio K., Kau S.W., Cristofanilli M., Buzdar A.U., Valero V., et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 2006, 24:1037-1044.
38. Kuerer H.M., Newman L.A., Smith T.L., Ames F.C., Hunt K.K., Dhingra K., et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999, 17:460-469.
39. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717. Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
40. Yerushalmi R., Hayes M.M., Gelmon K.A. Breast carcinomas-rare types: review of the literature. Ann Oncol 2009, 20:1763-1770.
41. Reis-Filho J.S., Milanezi F., Steele D., Savage K., Simpson P.T., Nesland J.M., et al. Metaplastic breast carcinomas are basal-like tumors. Histopathology 2006, 49:10-21.
42. Straver M.E., Glas A.M., Hannemann J., Wesseling J., van de Vijver MJ Th, Rutgers E.J., et al. The 70-gene signature as as response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat 2010, 119:551-558.
43. Gianni L., Zambetti M., Clark K., Barker J., Cronin M., Wu J., et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 2005, 23:7265-7277.
44. Tanaka-Akashi S., Shimizu C., Ando M., Shibata T., Katsumata N., Kouno T., et al. 21-Gene expression profile assay on core needle biopsies predicts responses to neoadjuvant endocrine therapy in breast cancer patients. Breast 2009, 18:171-174.
45. Goldhirsch A., Wood W.C., Coates A.S., Gelber R.D., Thürlimann B., Senn H.J., et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol 2011, 22:1736-1747.